Immunotherapy

Results show that combining hormonal therapy with immunotherapy may offer a promising alternative to chemotherapy for advanced salivary gland cancer. The treatment combined goserelin, a hormone therapy, with pembrolizumab. The study reported a 27.7% overall response rate and a 78% disease control rate. Patients stayed on treatment for a median of 12.1 months, and some […]

Melanoma treatment is moving toward personalized cancer vaccines designed for each patient’s unique genetic profile. While promising, their use is currently limited by how long they take to produce. Because these vaccines are custom-made, manufacturing takes about 6 to 9 weeks. This creates a critical waiting period, meaning the treatment works best for patients whose

A phase 2 study called CaboPoint shows that cabozantinib is an effective second-line treatment for patients with advanced kidney cancer whose disease has progressed after modern immunotherapy. The trial included 127 patients with advanced renal cell carcinoma who had already received checkpoint inhibitor-based treatments. Some had prior dual immunotherapy, while others had immunotherapy combined with

New research is changing how certain colon cancers are treated. The study focuses on patients with stage 3 colon cancer who have a genetic feature called dMMR, which affects about 15% of cases and has traditionally responded poorly to standard chemotherapy. Researchers found that adding the immunotherapy drug atezolizumab to chemotherapy after surgery reduced the

A new study shows that bortezomib, a drug used for Multiple Myeloma, may help overcome resistance to immunotherapy in Non-Small Cell Lung Cancer. Researchers found the drug prevents the breakdown of the interferon-gamma receptor (IFNGR1), a key molecule tumors often destroy to avoid immune detection. By preserving this receptor, cancer cells become more visible and

Final results from the Phase 2 OVATION 2 trial show that adding IMNN-001 to standard chemotherapy significantly improves survival for women with newly diagnosed advanced ovarian cancer. The study found that median overall survival increased by 14.7 months with IMNN-001 plus chemotherapy compared to chemotherapy alone (45.1 vs. 30.4 months). For patients who also received

Final results from the Phase 3 ARES trial, presented at the EBMT 52nd Annual Meeting, show that the fecal microbiotherapy MaaT013 significantly improves survival for patients with life-threatening, drug-resistant gut graft-versus-host disease (aGVHD). Patients with gastrointestinal aGVHD who fail steroids and ruxolitinib usually face a median survival of about 86 days. In the trial, MaaT013—a

A retrospective study shows that skin-related side effects are very common in patients treated with tebentafusp for metastatic uveal melanoma, with important findings in non-White patients. About 76.5% of patients developed a rash, often after the first infusion. Other common symptoms included itching, swelling, and dry skin. The study also found differences by race, with

A secondary analysis of the Phase 3 KEYNOTE-716 trial, published in JAMA Network, shows that adjuvant pembrolizumab continues to provide strong benefits for patients with resected stage IIB or IIC melanoma. The treatment significantly improved recurrence-free survival, with a 48-month rate of 68.7% compared to 56.5% for placebo. The study also found that immunotherapy did

A growing issue in cancer care is the long-term side effects from immunotherapy. These immune-related adverse effects can appear more than a year after treatment begins or last for years because immunotherapy reshapes the immune system. These delayed effects are hard to recognize, as they can resemble aging, other illnesses, or cancer itself. Patients often